AstraZeneca
San Carlos, California, United States
Dr. Shah is the Global Head of Multiple Myeloma Clinical Development & Strategy in the Haematology Research & Development Department at AstraZeneca. Prior to this she was Professor of Clinical Medicine in the Division of Hematology-Oncology at University of California San Francisco. Her career has centered on multiple myeloma, from MGUS to relapsed/refractory disease. Dr. Shah’s research has focused on multiple myeloma clinical trials, specifically immunotherapy and cellular therapy. She performed the first-in-human clinical trial of cord blood-derived natural killer cell therapy for myeloma and was a lead principal investigators for the BMT CTN 1401 dendritic cell vaccine trial for myeloma patients. Additionally, she served as the institutional PI for numerous cellular therapy and immunotherapy protocols. Dr. Shah is also interested in outcomes research for myeloma patients undergoing autologous transplantation/ cellular therapy and led a randomized trial to determine the impact of stem cell dose on symptoms during transplant. She has published on the link between patient reported outcomes and physical testing in this context and is conducting a study to investigate digital life coaching during transplant recovery. She has been heavily involved in the myeloma research community and led the effort to define myeloma-transplant practice guidelines for the American Society of Transplantation and Cellular Therapy (ASTCT). She also serves as a Co-Chair for the Plasma Cell Disorders Working Committee at the Center for International Blood & Marrow Transplant Research (CIBMTR) and is a member of the American Society of Hematology Scientific Committee on Plasma Cell Neoplasia.
Disclosure information not submitted.
Friday, October 21, 2022
3:00 PM – 4:30 PM
Friday, October 21, 2022
3:30 PM – 3:45 PM
Friday, October 21, 2022
4:00 PM – 4:25 PM